welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors̵...Colorectal cancer (CRC) is a leading cau...
-
Does a Selective Cyclooxygenase-2 Inhibitor (Tiracoxib) Induce Clinically Sufficient Suppression of Adenomas in Pati...BACKGROUND : There have been few placebo...
-
Sulindac Sulfone is Most Effective in Modulating Beta-Catenin-Mediated Transcription in Cells with Mutant APCSulindac sulfone (FGN-1, Aptosyn), a met...
-
In a Select Group of Patients Meeting Strict Clinical Criteria and Undergoing Ileal Pouch-Anal Anastomosis, the Omis...PURPOSE : Ileal pouch-anal anastomosis i...
-
Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps TrialOBJECTIVES: Subjects in the Prevention ...
-
NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomasInterim results from a randomized clinic...
-
Proctocolectomy for Ulcerative Colitis or Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=zlxBwxKX...